Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
Completed · Phase 2
Conditions studied: Glomerulonephritis
In brief
The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).
Key facts
- Study ID
- NCT03832114
- Run by
- Novartis Pharmaceuticals
- People needed
- 27
- Starts
- 2019-02-20
- Expected to finish
- 2021-04-23
- Last updated by the study team
- 2024-01-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Iowa City, Iowa, United States
- Novartis Investigative Site — Montpellier, France
- Novartis Investigative Site — Paris, France
- Novartis Investigative Site — Essen, Germany
- Novartis Investigative Site — Ranica, BG, Italy
- Novartis Investigative Site — Barcelona, Catalonia, Spain
- Novartis Investigative Site — Madrid, Spain
- Novartis Investigative Site — London, United Kingdom
- Novartis Investigative Site — Newcastle upon Tyne, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.